LCTG 001
Alternative Names: LCTG-001Latest Information Update: 10 Feb 2025
At a glance
- Originator Lactiga
- Class Antibodies; Antivirals
- Mechanism of Action IgA specific serine endopeptidase replacements; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Common variable immunodeficiency
- No development reported COVID 2019 infections
Most Recent Events
- 03 Feb 2025 Preclinical development in Common-variable-immunodeficiency(Prevention) is underway in USA
- 03 Feb 2025 LCTG 001 receives Orphan Drug status for Common Variable Immunodeficiency in USA, prior to February 2025
- 03 Feb 2025 The US FDA grants Rare Pediatric Disease Designation (RPD) to LCTG 001 for the treatment of Common Variable Immunodeficiency in USA, prior to February 2025